Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2008

Peng HQ, Greenwald BD, Tavora FR, Kling E, Darwin P, Rodgers WH, et al. Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas. Diagn Cytopathol. 2008;36(5):290-6.

Kenney B, Tormey CA, Qin L, Sosa JA, Jain D, Neto A. Adult nesidioblastosis. Clinicopathologic correlation between pre-operative selective arterial calcium stimulation studies and post-operative pathologic findings. JOP. 2008;9(4):504-11.

Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 2008;13(4):343-54.

Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008;143(5):654-60.

Milette F. De novo intraepidermal epithelioid melanocytic dysplasia? J Cutan Pathol. 2008;35(12):1148-9; author reply 1150.

Li M-, Sanchez T, Pappalardo A, Lynch KR, Hla T, Ferrer F. Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2. Mol Cancer Res. 2008;6(10):1649-56.

Hamadani M, Magro CM, Porcu P. CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). Br J Haematol. 2008;140(2):122.

Magro CM, Dyrsen ME. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. J Cutan Pathol. 2008;35(11):1040-9.

Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(3):493-9.

England P, Westblade LF, Karimova G, Robbe-Saule V, Norel F, Kolb A. Binding of the unorthodox transcription activator, Crl, to the components of the transcription machinery. J Biol Chem. 2008;283(48):33455-64.